Comparing Myovant Sciences (MYOV) and Fortress Biotech (FBIO)

Myovant Sciences (NASDAQ: MYOV) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitabiliy, risk, analyst recommendations, institutional ownership, dividends and earnings.


This table compares Myovant Sciences and Fortress Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myovant Sciences N/A -49.28% -45.83%
Fortress Biotech -269.14% -63.99% -34.99%

Valuation and Earnings

This table compares Myovant Sciences and Fortress Biotech’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Myovant Sciences N/A N/A -$55.80 million N/A N/A
Fortress Biotech $60.50 million 3.88 -$64.15 million ($1.36) -3.43

Myovant Sciences has higher revenue, but lower earnings than Fortress Biotech.

Institutional and Insider Ownership

12.9% of Fortress Biotech shares are owned by institutional investors. 31.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Myovant Sciences and Fortress Biotech, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myovant Sciences 0 0 5 0 3.00
Fortress Biotech 0 0 5 0 3.00

Myovant Sciences presently has a consensus target price of $19.50, indicating a potential upside of 72.57%. Fortress Biotech has a consensus target price of $10.60, indicating a potential upside of 127.47%. Given Fortress Biotech’s higher probable upside, analysts plainly believe Fortress Biotech is more favorable than Myovant Sciences.


Fortress Biotech beats Myovant Sciences on 5 of the 8 factors compared between the two stocks.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Fortress Biotech Company Profile

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply